• Who it affects: It can occur at any age, but most cases are identified in childhood or early adulthood. Both genders are equally affected, although certain genetic syndromes (e.g., Marfan syndrome) have a slight male predominance.
• Prevalence: Primary (non‑traumatic) ectopia lentis is rare, affecting roughly 1 in 10,000–20,000 individuals worldwide. However, among patients with Marfan syndrome the prevalence rises to >60%, and in homocystinuria it can be present in >90% of cases ^[1][2].

Symptoms

Symptoms vary with the degree of lens displacement and whether other ocular structures are involved.

• Blurred or double vision (diplopia): Most common; worsens when looking in the direction of lens displacement.
• Irregular astigmatism: The lens tilts, creating uneven curvature.
• Decreased visual acuity: May be mild (20/30) to severe (hand‑motion).
• Glare and halos: Light scattering from the misaligned lens.
• Eye strain or headache: Due to constant effort to focus.
• Visible lens displacement: In some patients, especially children, the lens edge can be seen moving with pupil dilation.
• Poor depth perception: Especially when one eye is more affected.
• Redness or pain: Typically only if a secondary complication such as inflammation or retinal detachment occurs.

Causes and Risk Factors

Ectopia lentis can be categorized as primary (congenital) or secondary (acquired).

Primary (Congenital) Causes

• Genetic syndromes – the most common:
  • Marfan syndrome (FBN1 mutation)
  • Homocystinuria (CBS gene deficiency)
  • Weill‑Marchesani syndrome (ADAMTS10, LTBP2)
  • Ehlers‑Danlos syndrome (various collagen genes)
• Isolated ectopia lentis – often autosomal dominant due to mutations in the ADAMTSL4 gene.
• Familial forms – inherited patterns without a recognized syndrome.

Secondary (Acquired) Causes

• Trauma – blunt or penetrating eye injury can rupture the zonular fibers that hold the lens.
• Ocular inflammation (e.g., uveitis) – chronic inflammation can weaken zonules.
• Systemic diseases – such as advanced diabetes mellitus, which may affect connective tissue.
• Surgical complications – after cataract extraction or vitrectomy.

Risk Factors

• Family history of ectopia lentis or related connective‑tissue disorders.
• Diagnosis of a systemic connective‑tissue disease (Marfan, homocystinuria, etc.).
• History of severe ocular trauma.
• High‑myopia patients, who may develop weak zonules over time.

Diagnosis

Diagnosis combines a detailed history, thorough eye examination, and targeted imaging.

Clinical Examination

• Visual acuity testing – baseline measurement of eye function.
• Slit‑lamp biomicroscopy – allows direct visualization of lens position and zonular integrity.
• Retinoscopy & refraction – identifies irregular astigmatism and helps plan corrective lenses.
• Gonioscopy – ensures the angle is not compromised, especially before surgery.

Imaging & Ancillary Tests

• Ultrasound biomicroscopy (UBM) – high‑resolution view of the anterior segment and zonules.
• Anterior segment optical coherence tomography (AS‑OCT) – non‑invasive cross‑sectional images to quantify lens tilt.
• A‑scan or B‑scan ultrasonography – useful when media opacity (e.g., cataract) blocks view.
• Genetic testing – panels for FBN1, CBS, ADAMTSL4, etc., recommended when a systemic syndrome is suspected.
• Systemic work‑up – for suspected Marfan (e.g., echocardiogram, aortic root measurement) or homocystinuria (plasma homocysteine levels).

Treatment Options

Management aims to restore clear vision, prevent complications, and address underlying systemic disease.

Non‑Surgical Approaches

• Corrective lenses – spectacles or rigid gas‑permeable (RGP) contact lenses can compensate for astigmatism caused by lens tilt.
• Pharmacologic therapy – only indicated for associated systemic disease:
  • Homocystinuria: pyridoxine (vitamin B6), betaine, dietary methionine restriction, and folate/B12 supplementation.
  • Marfan: beta‑blockers or angiotensin‑receptor blockers (e.g., losartan) to reduce aortic complications, though they do not affect the eye directly.
• Observation – Mild subluxation with stable vision may be monitored with regular eye exams every 6–12 months.

Surgical Options

Surgery is considered when visual acuity cannot be corrected with lenses, when the lens threatens other ocular structures, or when there is progressive subluxation.

1. Lens extraction (lensectomy) – removal of the displaced lens, often combined with:
   • Intraocular lens (IOL) implantation (scleral‑fixed, iris‑claw, or anterior chamber IOL) depending on zonular integrity.
   • Pars plana vitrectomy (PPV) to reduce vitreous traction.
2. Phacoemulsification with capsular tension rings (CTRs) – If enough zonules remain, a CTR can stabilize the capsule while the natural lens is removed and replaced with a posterior chamber IOL.
3. Scleral‑fixated IOLs – Sutured or glued IOLs positioned in the posterior chamber when capsular support is absent.
4. Anterior chamber IOLs – Reserved for cases where posterior fixation is impossible; careful endothelial monitoring required.

Success rates for modern lens‑sparing or lens‑replacing procedures exceed 85% for achieving 20/40 vision or better, with low rates of severe complications when performed by experienced vitreoretinal surgeons ^[3].

Lifestyle & Supportive Measures

• Regular follow‑up with an ophthalmologist familiar with ectopia lentis.
• Avoid high‑impact sports without protective eyewear.
• Maintain systemic disease control (e.g., low‑dose aspirin for Marfan, dietary control for homocystinuria).

Living with Lens Subluxation (Ectopia Lentis)

Adapting to visual changes and preventing complications are central to quality of life.

Visual Aids

• Choose high‑index lenses to minimize thickness.
• Consider custom RGP lenses or piggy‑back soft‑over‑RGP systems for irregular astigmatism.
• Low‑vision rehabilitation services can provide magnifiers, electronic reading aids, or orientation training if vision remains limited.

Protective Measures

• Wear polycarbonate safety glasses during sports or when using power tools.
• Use sunglasses with UV protection to reduce cataract risk.

Systemic Health Monitoring

• For Marfan syndrome: Annual cardiology review, echocardiogram every 1–2 years, and blood pressure monitoring.
• For homocystinuria: Quarterly plasma homocysteine levels and dietary counseling.

Psychosocial Support

• Connect with patient advocacy groups (e.g., Marfan Foundation, Homocystinuria Association).
• Consider counseling if visual impairment affects daily activities or self‑esteem.

Prevention

Because many cases are genetic, primary prevention is limited, but several strategies can reduce risk of progression or secondary subluxation.

• Genetic counseling – Recommended for families with known autosomal‑dominant mutations.
• Protect eyes from trauma – Use protective eyewear in high‑risk environments.
• Control systemic diseases – Early treatment of homocystinuria and regular cardiac surveillance in Marfan syndrome.
• Regular ophthalmic exams – Early detection of subtle lens shift allows timely correction before amblyopia or severe astigmatism develops.

Complications

If left untreated or inadequately managed, ectopia lentis can lead to serious ocular and systemic problems.

• Progressive myopia or high astigmatism – May become refractory to glasses.
• Amblyopia – Especially in children with unilateral or markedly asymmetrical subluxation.
• Secondary cataract – Lens opacity from chronic zonular stress.
• Glaucoma – Angle closure can occur if the lens moves forward.
• Retinal detachment – Traction on the peripheral retina from a displaced lens or vitreous changes.
• Corneal endothelial damage – From an anteriorly displaced lens touching the cornea.
• Systemic sequelae – For patients with Marfan or homocystinuria, the eye findings may be early indicators of life‑threatening cardiovascular disease.

When to Seek Emergency Care

References:

1. Mayo Clinic. Ectopia Lentis – Symptoms & Causes. Accessed April 2026.
2. National Institutes of Health, Genetics Home Reference. Homocystinuria. Updated 2025.
3. Cleveland Clinic. Ectopia Lentis Treatment Options. Reviewed 2025.
4. World Health Organization. Eye Health Fact Sheet. 2024.